Relative Contribution of Brain Insulin Action for Postprandial Metabolism

Last updated: March 26, 2024
Sponsor: University of Ulm
Overall Status: Active - Recruiting

Phase

N/A

Condition

Metabolic Disorders

Treatment

Oral glucose tolerance test with double-tracer dilution and intranasal placebo spray

Oral glucose tolerance test with double-tracer dilution and intranasal insulin spray

Clinical Study ID

NCT06295640
300/2022
  • Ages 18-30
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this clinical trial is to clarify (i) the contribution of brain insulin action on regulation of systemic metabolism, (ii) sex-specific differences in the central regulation and (iii) the influence of the menstrual cycle in women.

Therefore, participants will undergo oral glucose tolerance tests combined with a double tracer dilution technique. This approach will be compared between days with insulin delivery to the brain as nasal spray and days with placebo spray.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • BMI < 24 kg/m2
  • no known primary diseases
  • no hormonal contraception

Exclusion

Exclusion Criteria:

  • Alcohol or drug abuse
  • Smoking
  • At screening: Hb < 12 g/dl for women and Hb < 14 g/dl for men
  • Any (clinical) condition that would endanger participant's safety or questionscientific success according to a physician's opinion.

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Oral glucose tolerance test with double-tracer dilution and intranasal placebo spray
Phase:
Study Start date:
March 18, 2024
Estimated Completion Date:
January 31, 2026

Study Description

This research project aims to investigate to what extent brain insulin action is responsible for the control of postprandial metabolism compared to direct effects of insulin in peripheral target tissues. Furthermore, the study will investigate sex differences and the influence of the menstrual cycle on brain-derived coordination of postprandial signaling for metabolic control.

Therefore, insulin action in the brain will be introduced by application of insulin as nasal spray (on one day) versus carrier solution as placebo nasal spray (on another day) in a randomized, blinded fashion. Spray administration will be performed 15 minutes before a 75 gram oral glucose tolerance test that will introduce a postprandial state. On placebo day, the known spillover of tiny amounts of nasal insulin into the systemic circulation will be mimicked by an appropriate i.v. insulin bolus. This approach will be combined with a double-tracer dilution technique. Labeled glucose ([6,6-2H]glucose) will be infused 120 minutes before and during the OGTT (180 min) and will be used to address endogenous glucose production. The glucose drink from the OGTT will be enriched with [U-13C6]glucose to compute the glucose appearance rate (Ra). Basal endogenous glucose production will be calculated as well as post-load endogenous glucose production and rates of glucose disappearances (Rd). Using this approach, brain-derived regulation of postprandial metabolism including endogenous glucose production, glucose disappearance, insulin secretion, and secretion of proglucagon-cleavage products (incretins) will be examined.

Connect with a study center

  • Universityhospital Ulm

    Ulm, 89081
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.